Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)

Next Previous
X
Search
Trial Profile

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Datopotamab deruxtecan (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms TROPION-LUNG01
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 03 Sep 2024 According to an AstraZeneca media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress, September 13 to 17, 2024.
    • 03 Sep 2024 According to an AstraZeneca media release, a late-breaking oral presentation at WCLC will showcase OS data from the TROPION-Lung01 Phase III trial evaluating datopotamab deruxtecan in patients with previously treated locally advanced or metastatic NSCLC.
    • 03 Sep 2024 According to an AstraZeneca media release, a late-breaking Presidential Symposium at WCLC of exploratory results from the application of companys proprietary computational pathology platform, quantitative continuous scoring (QCS), to tissue samples collected in TROPION-Lung01 will demonstrate the potential of TROP2, as measured by QCS, as a predictive biomarker for datopotamab deruxtecan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top